Alzheimer's Screening and Prevention (ASAP) Act of 2025
November 19, 2025
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
Where This Stands
Currently in_committee. The next step in the legislative lifecycle is Floor Vote.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →The Frame
Medicare beneficiaries would gain insurance coverage for specific blood-based tests designed to detect Alzheimer's and dementia in pre-symptomatic or early stages starting in 2028.
Potentially affected actors named in the source documents. Mention is not a position.
Medicare beneficiaries
Individuals enrolled in Medicare would have access to insurance coverage for specific Alzheimer's and dementia screening tests.
Medical diagnostic companies
Companies producing FDA-approved blood-based dementia screening tests would be eligible for Medicare reimbursement.
Current stage: in_committee.
Floor Vote.
Summary
Key Facts
- The bill is officially titled the 'Alzheimer's Screening and Prevention Act of 2025' or the 'ASAP Act'.
- Medicare coverage for blood-based early detection screening tests for Alzheimer's and related dementias would begin on January 1, 2028.
- Eligible tests must be cleared, classified, or approved under the Federal Food, Drug, and Cosmetic Act.
- Covered tests include genomic sequencing blood tests and other equivalent tests (such as single-analyte, cell-free nucleic acids, or protein expression tests) as determined by the Secretary of Health and Human Services.
- The bill amends Section 1861 of the Social Security Act to define these screening tests.
- The bill amends Section 1833 of the Social Security Act to establish payment provisions for these tests.
- The bill was introduced in the House of Representatives on November 19, 2025.
Frequently Asked Questions
When would this coverage start?
What kind of tests would be covered?
Why It Matters
Medicare beneficiaries would gain insurance coverage for specific blood-based tests designed to detect Alzheimer's and dementia in pre-symptomatic or early stages starting in 2028.
News Coverage
Lobbying Activity
ACADIA PHARMACEUTICALS
2026
“Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.”
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Proactive Medicare Coverage
The bill represents a shift toward covering pre-symptomatic screening for neurodegenerative diseases, rather than just diagnostic testing after symptoms appear.
Connected Entities
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy15Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools